Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability and Effectiveness of CGB 500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis: a Randomized, Double-Blind, Vehicle-Controlled Study

NCT05487963 is registered in ClinicalTrials.gov with CAGE Bio Inc. as lead sponsor.

NCT NCT05487963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05487963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability and Effectiveness of CGB 500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis: a Randomized, Double-Blind, Vehicle-Controlled Study
Lead sponsor
CAGE Bio Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 9, 2022
Completion date
July 30, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis